^
    Back
    Association details:
    Biomarker:WWP2 underexpression
    Cancer:Multiple Myeloma
    Drug:bortezomib (Proteasome inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: D – Preclinical
    Source:
    Carcinogenesis
    Title:

    DKK1 Suppresses WWP2 to Enhance Bortezomib Resistance in Multiple Myeloma via Regulating GLI2 Ubiquitination

    Published date:
    09/21/2021
    Excerpt:
    In the current study, we found WWP2, an E3 ubiquitin-protein ligase, was downregulated in the bortezomib-resistant cells...Therefore, DKK1-induced WWP2 downregulation improved GLI2 stability and activation of Hh signaling pathway, contributing to the resistance to bortezomib of MM cells.
    DOI:
    10.1093/carcin/bgab086